FreshPatents.com Logo
Enter keywords:  

Track companies' patents here: Public Companies RSS Feeds | RSS Feed Home Page
Popular terms

[SEARCH]

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

Receptor patents



      
           
This page is updated frequently with new Receptor-related patent applications. Subscribe to the Receptor RSS feed to automatically get the update: related Receptor RSS feeds. RSS updates for this page: Receptor RSS RSS


Date/App# patent app List of recent Receptor-related patents
05/21/15
20150142011
 Implant tool and improved electrode design for minimally invasive procedure patent thumbnailnew patent Implant tool and improved electrode design for minimally invasive procedure
Devices and methods of use for introduction and implantation of an electrode as part of a minimally invasive technique. An implantable baroreflex activation system includes a control system having an implantable housing, an electrical lead, attachable to the control system, and an electrode structure.
Cvrx, Inc.
05/21/15
20150141669
 Prodrug of fluorine-containing amino acid patent thumbnailnew patent Prodrug of fluorine-containing amino acid
Provided are a fluorine-containing amino acid prodrug represented by general formula (i) that makes a fluorine-containing amino acid which is a group 2 metabotropic glutamate receptor agonist into a prodrug, or a pharmaceutically acceptable salt thereof. More specifically, provided is a prodrug that increases the in vivo exposure and enhances the oral absorbability and other mucosal absorbability of a parent compound that acts on group 2 metabotropic glutamate receptors as an agent for the treatment or prevention of diseases in which group 2 metabotropic glutamate receptors are said to be involved, such as: schizophrenia, anxiety disorder and its related diseases, depression, bipolar disorder, epilepsy, developmental disorders, sleep disorders, and other neuropsychiatric diseases; and drug dependence, cognitive disorders, alzheimer's disease, huntington's chorea, parkinson's disease, movement disorders associated with muscular rigidity, cerebral ischemia, cerebral insufficiency, spinal cord disorders, cephalopathy, and other neurological diseases..
Taisho Pharmaceutical Co., Ltd.
05/21/15
20150141641
 Method for producing 4,4,7-trifluoro-1,2,3,4-tetrahydro-5h-1-benzazepine compound and intermediate used in the method patent thumbnailnew patent Method for producing 4,4,7-trifluoro-1,2,3,4-tetrahydro-5h-1-benzazepine compound and intermediate used in the method
The present invention provides a method for producing a 4,4,7-trifluoro-1,2,3,4-tetrahydro-5h-1-benzazepine compound which has an superior agonistic activity to an arginine vasopressin v2 receptor and is useful as an active ingredient for a pharmaceutical composition for preventing and/or treating urinary frequency, urinary incontinence, enuresis, central diabetes insipidus, nocturia, nocturnal enuresis, or the like; and useful intermediates for use in the methods. The production method of the present invention is suitable for the industrial production of a medicament, because of a smaller number of steps, a higher yield, and a lower cost, as compared with the methods in the related art..
Astellas Pharma Inc.
05/21/15
20150141626
 Reducing the immunogenicity of fusion proteins patent thumbnailnew patent Reducing the immunogenicity of fusion proteins
Disclosed are compositions and methods for producing fusion proteins with reduced immunogenicity. Fusion proteins of the invention include a junction region having an amino acid change that reduces the ability of a junctional epitope to bind to mhc class ii, thereby reducing its interaction with a t-cell receptor.
Merck Patent Gmbh
05/21/15
20150141622
 Flt4 (vegfr-3) as a target for tumor imaging and anti-tumor therapy patent thumbnailnew patent Flt4 (vegfr-3) as a target for tumor imaging and anti-tumor therapy
The present invention provide purified flt4 receptor tyrosine kinase polypeptides and fragments thereof, polynucleotides encoding such polypeptides, antibodies that specifically bind such polypeptides, and uses therefor.. .
Vegenics Limited
05/21/15
20150141520
 Stabilized pharmaceutical compositions of fingolimod and process for preparation thereof patent thumbnailnew patent Stabilized pharmaceutical compositions of fingolimod and process for preparation thereof
Stabilized pharmaceutical compositions comprising a s1p receptor modulator as an active agent(s), process of preparation and method of using the same are provided. The present invention also relates to stabilized pharmaceutical compositions comprising fingolimod, or pharmaceutically acceptable salts, esters, hydrates and solvates thereof, process of preparation and method of using the same..
05/21/15
20150141482
 1-(p-tolyl)cyclopropyl substituted bridged spiro[2.4]heptane derivatives as alx receptor agonists patent thumbnailnew patent 1-(p-tolyl)cyclopropyl substituted bridged spiro[2.4]heptane derivatives as alx receptor agonists
Wherein r1 is as defined in the description, their preparation and their use as pharmaceutically active compounds.. .
05/21/15
20150141480
 Carbohydrate-selective receptors patent thumbnailnew patent Carbohydrate-selective receptors
The present invention is directed to a new class of synthetic carbohydrate receptor compounds comprising formula i as described herein: (i). Other aspects of the present invention relate to pharmaceutical compositions and pharmaceutical delivery vehicles comprising the compound of formula (i) the present invention is also directed to methods of treatment and diagnosis that involve the administration of a compound of formula (i)..
New York University
05/21/15
20150141477
 Pyrazole derivatives and their use as lpar5 antagonists patent thumbnailnew patent Pyrazole derivatives and their use as lpar5 antagonists
The present invention relates to compounds of the formula (i), wherein the residues r1 to r5, v, g and m have the meanings indicated in the claims. The compounds of the formula (i) are valuable pharmacologically active compounds for use in the treatment of diverse disorders, for example cardiovascular disorders like thromboembolic diseases or restenoses.
Sanofi
05/21/15
20150141471
 Pyridine derivatives and their use in the treatment of conditions associated with pathological thrombus formation patent thumbnailnew patent Pyridine derivatives and their use in the treatment of conditions associated with pathological thrombus formation
The present invention relates to compounds of the formula (i), wherein the residues r1 to r6, v, g and m have the meanings indicated in the claims. The compounds of the formula i are valuable pharmacologically active compounds for use in the treatment of diverse disorders, for example cardiovascular disorders like thromboembolic diseases or restenoses.
Sanofi
05/21/15
20150141452
new patent

Compositions for affecting weight loss


Disclosed are compositions for affecting weight loss comprising a first compound and a second compound, where the first compound is an opioid antagonist and the second compound causes increased agonism of a melanocortin 3 receptor (mc3-r) or a melanocortin 4 receptor (mc4-r) compared to normal physiological conditions. Also disclosed are methods of affecting weight loss, increasing energy expenditure, increasing satiety in an individual, or suppressing the appetite of an individual, comprising identifying an individual in need thereof and treating that individual to antagonize opioid receptor activity and to enhance α-msh activity..
Orexigen Therapeutics, Inc.
05/21/15
20150141445
new patent

Tricyclic compounds having cytostatic and/or cytotoxic activity and methods of use thereof


The present invention provides tricyclic compounds having cytostatic and cytotoxic activity in a single molecule having receptor tyrosine kinase(s), dihydrofolate reductase, thymidylate synthase and/or dihydroorotate dehydrogenase inhibitory activity, which are useful as anti-angiogenic and anti-tumor agents. Also provided are methods of utilizing these inhibitors to treat tumor cells and other proliferative diseases and disorders..
Duquesne University Of The Holy Ghost
05/21/15
20150141444
new patent

N-methyl tetrahydroquinoline m1 receptor positive allosteric modulators


The present invention is directed to n-methyl tetrahydroquinoline compounds of formula (i) which are m1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the m1 receptor is involved, such as alzheimer's disease, schizophrenia, pain or sleep disorders. The invention is also directed to pharmaceutical compositions comprising the compounds, and to the use of the compounds and compositions in the treatment of diseases mediated by the m1 receptor..
Merck Sharp & Dohme Corp.
05/21/15
20150141433
new patent

N-arylmethyl sulfonamide negative modulators of nr2a


Compounds that selectively negatively modulate nmda receptors containing an nr2a subunit, pharmaceutical compositions comprising the compounds, and methods of treating a disease using the compounds are disclosed.. .
Mnemosyne Pharmaceuticals, Inc.
05/21/15
20150141432
new patent

Piperidin-4-yl-pyridazin-3-ylamine derivatives as fast dissociating dopamine 2 receptor antagonists


The present invention relates to compounds that are fast dissociating dopamine 2 receptor antagonists, processes for preparing these compounds, pharmaceutical compositions comprising these compounds as an active ingredient. The compounds find utility as medicines for treating or preventing central nervous system disorders, for example schizophrenia, by exerting an antipsychotic effect without motor side effects..
Janssen Pharmaceutica N.v.
05/21/15
20150141428
new patent

Trka kinase inhibitors, compositions and methods thereof


The present invention is directed to benzyl urea compounds, which are tropomyosin-related kinase (trk) family protein kinase inhibitors, and hence may be useful in the treatment of pain, inflammation, cancer, restenosis, atherosclerosis, psoriasis, thrombosis, a disease, disorder, injury, or malfunction relating to dysmyelination or demyelination or a disease or disorder associated with abnormal activities of nerve growth factor (ngf) receptor trk-a, trk-b and/or trk-c.. .
Merck Sharp & Dohme Corp.
05/21/15
20150141425
new patent

C5ar antagonists


Compounds are provided that are modulators of the c5a receptor. The compounds are substituted piperidines and are useful in pharmaceutical compositions, methods for the treatment of diseases and disorders involving the pathologic activation of c5a receptors..
Chemocentryx, Inc.
05/21/15
20150141421
new patent

6,7-dialkoxy quinazoline derivatives and methods of treating drug resistant and other tumors


Methods of inhibiting a receptor tyrosine kinase in a subject in need thereof. Methods of inhibiting the growth of a tumor cell in a subject in need thereof.
05/21/15
20150141419
new patent

Diaryl[a, g]quinolizidine compound, preparation method therefor, pharmaceutical composition, and uses thereof


The present invention relates to a diarylo[a,g]quinolizidine compound of formula (i), enantiomer, diastereoisomer, racemate, mixture, pharmaceutically acceptable salt, crystalline hydrate or solvate thereof; the preparation method thereof, and uses thereof in preparing an experimental model drugs related to dopamine receptors and 5-ht receptors or a medicament for treating or preventing a disease related to dopamine receptors and 5-ht receptors.. .
Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences
05/21/15
20150141416
new patent

Hydroxybupropion analogues for treating drug dependence


The invention provides hydroxybupropion analogues capable of inhibiting the reuptake of one or more monoamines and/or acting as antagonists at nicotinic acetylcholine receptors. The compounds may selectively bind to one or more monoamine transporters, including those for dopamine, norepinephrine, and serotonin and/or may selectively bind to one or more nicotinic acetylcholine receptor subtypes.
Virginia Commonwealth University
05/21/15
20150141410
new patent

Gpr17 receptor modulators


Chemical compounds are provided which act on gpr17 receptors and are useful in the treatment or amelioration of chronic and/or acute neurodegenerative diseases, such as multiple sclerosis, inflammatory diseases, pathologies involving the immune system, cardiovascular diseases, and renal diseases.. .
Fondazione Italiana Sclerosi Multipla - Fish Onlus
05/21/15
20150141403
new patent

1,2,4-triazolo [4,3-a] pyridine derivatives and their use for the treatment of prevention of neurological and psychiatric disorders


Wherein all radicals are as defined in the claims. The compounds according to the invention are positive allosteric modulators of the metabotropic glutamate receptor subtype 2 (“mglur2”), which are useful for the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which the mglur2 subtype of metabotropic receptors is involved.
05/21/15
20150141391
new patent

Systems and methods for determining a treatment course of action


The present disclosure relates to methods of determining a treatment course of action. In particular, the present disclosure relates to mutations in the gene encoding estrogen receptor and their association with responsiveness to estrogen therapies for cancer..
The Regents Of The University Of Michigan
05/21/15
20150141387
new patent

Pharmaceutical product comprising a p38 kinase inhibitor and a second active ingredient


The invention provides a pharmaceutical product, kit or composition comprising a first active ingredient which is n-cyclopropyl-3-fluoro-4-methyl-5-[3-[[1-[2-[2-(methylamino)ethoxy]phenyl]cyclopropyl]amino]-2-oxo-1(2h)-pyrazinyl]-benzamide or a salt thereof, and a second active ingredient selected from: a non-steroidal glucocorticoid receptor (gr receptor) agonist; an antioxidant; a β2 adrenoceptor agonist; a ccr1 antagonist; a chemokine antagonist (not ccr1); a corticosteroid; a crth2 antagonist; a dpi antagonist; an histone deacetylase activator; an ikk2 kinase inhibitor; a cox inhibitor; a lipoxygenase inhibitor; a leukotriene receptor antagonist; a maba compound; an mpo inhibitor; a muscarinic antagonist; a pde4 inhibitor; a pparγ agonist; a protease inhibitor; a statin; a thromboxane antagonist; a vasodilator; or, an enac blocker (epithelial sodium-channel blocker); and its use in the treatment of respiratory disease.. .
Astrazeneca Ab
05/21/15
20150141385
new patent

Methods useful for vitamin d deficiency and related disorders


Methods for diagnosing, treating, and preventing catabolism-related vitamin d deficiency and related disorders, related compositions, apparatus and kits, are disclosed. A method involves measuring cyp24 expression and/or activity, or a proxy thereof such as fgf23 level, in a patient and correlating abnormally elevated cyp24 expression and/or activity with catabolism-related vitamin d deficiency or with susceptibility for catabolism-related vitamin d deficiency.
Opko Ireland Global Holdings, Ltd.
05/21/15
20150141364
new patent

Compositions including triciribine and epidermal growth factor receptor inhibitor compounds or salts thereof and methods of use thereof


This application relates to combination therapies including triciribine compounds and epidermal growth factor receptor inhibitor compounds, particularly erlotinib-like compounds and compositions with reduced toxicity for the treatment and prevention of tumors, cancer, and other disorders associated with abnormal cell proliferation.. .
University Of South Florida
05/21/15
20150141347
new patent

Murine anti-ny-eso-1 t cell receptors


The invention provides an isolated or purified t cell receptor (tcr) having antigenic specificity for ny-eso-1. Also provided are related polypeptides, proteins, nucleic acids, recombinant expression vectors, isolated host cells, populations of cells, antibodies, or antigen binding portions thereof, and pharmaceutical compositions.
The United States Of America, As Represented By The Secretary, Department Of Health & Human Serv.
05/21/15
20150141336
new patent

Pancreatic peptide compounds and use


The invention relates to novel use of pancreatic polypeptides as well as novel pancreatic polypeptides and compositions thereof. Such peptides can be used in treating or preventing conditions responsive to y4 and/or y5 receptor activation, such as cachexia..
Novo Nordisk A/s
05/21/15
20150141283
new patent

Il-17 homologous polypeptides and therapeutic uses thereof


The present invention is directed to novel polypeptides having sequence identity with il-17, il-17 receptors and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.
Genentech, Inc.
05/21/15
20150141261
new patent

High throughput sequencing of multiple transcripts of a single cell


The present disclosure generally relates to sequencing two or more genes expressed in a single cell in a high-throughput manner. More particularly, the present disclosure relates to a method for high-throughput sequencing of pairs of transcripts co expressed in single cells (e.g., antibody vh and vl coding sequence) to determine pairs of polypeptide chains that comprise immune receptors..
Board Of Regents, The University Of Texas Systems
05/21/15
20150140683
new patent

Method for producing soluble fcr as fc-fusion with inert immunoglobulin fc-region and uses thereof


Herein is a fusion polypeptide with the formula r1-fc-r2, wherein r1 denotes a first fc-receptor, r2 denotes a second fc-receptor, and fc denotes a heavy chain fc-region polypeptide, wherein r1 or r2 or both are present, wherein fc does not substantially bind to r1 and/or r2 and uses thereof.. .
Hoffmann-la Roche Inc.
05/21/15
20150140555
new patent

Method of identifying foetal erythroblast


There is provided a method for identifying at least one foetal erythroblast the method comprising: (a) detecting the expression of at least one foetal erythroblast specific marker selected from the group consisting of neutral amino acid transporter b (slc1a5), solute carrier family 3 (activators of dibasic and neutral amino acid transport) member 2 isoform a (slc3a2), splice isoform a of chloride channel protein 6, transferrin receptor protein 1, splice isoform 3 of protein gpr107 precursor, olfactory receptor 11h4, splice isoform 1 of protein c9orf5, cleft lip and palate transmembrane protein 1, bcg induced integral membrane protein bigm103, antibacterial protein fall-39 precursor, caax prenyl protease 1 homolog, splice isoform 2 of synaptophysin-like protein, vitamin k epoxide reductase complex subunit 1-like protein 1, splice isoform 1 of protein c20orf22 (abhd12), hypothetical protein dkfzp564k247 (hypoxia induced gene 1 protein) (ipi accession no. Ipi00295621), hypothetical protein dk-fzp586c1924 (ipi accession no.
National University Of Singapore
05/21/15
20150140120
new patent

Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics


Materials and methods are provided for producing and using aptamers useful as oncology therapeutics capable of binding to pdgf, pdgf isoforms, pdgf receptor, vegf, and vegf receptor or any combination thereof with great affinity and specificity. The compositions of the present invention are particularly useful in solid tumor therapy and can be used one or in combination with known cytotoxic agents for the treatment of solid tumors.
Archemix Llc
05/21/15
20150140087
new patent

Pharmaceutical compositions of metabotropic glutamate 5 receptor (mglu5) antagonists


Pharmaceutical compositions of metabotropic glutamate 5 receptor (mglu5) antagonists or a pharmacologically acceptable salt thereof are disclosed. The compositions contain the therapeutic active compound with non-ionic polymer and ionic polymer, binder and fillers in either matrix pellet, matrix tablet or coated pellets.
F. Hoffmann-la Roche Ag
05/21/15
20150140016
new patent

Molecular determinants of myeloma bone disease and uses thereof


The present invention is drawn to understanding lytic bone diseases. In this regard, the present invention discloses mechanism by which wnt signaling antagonist inhibits bone differentiation.
Board Of Trustees Of The University Of Arkansas
05/21/15
20150140011
new patent

Il-6 binding molecules


The present invention provides binding molecules (e.g., antibodies or antigen binding fragments thereof) that specifically bind to and inhibit the biological activity of il-6 (e.g., human, mouse and non-human primate il-6). In a preferred embodiment, the antibodies or antigen binding fragments of the invention bind to il-6 and inhibit its binding to an il-6 receptor.
Argen-x B.v.
05/21/15
20150140009
new patent

Compositions and methods for the treatment of radiation exposure


The invention provides methods for the treatment of radiation exposure featuring agents that interfere with the expression, production, release, accumulation, or activity of a tnfα, il6, egf, il1-alpha, il1-beta, g-csf, mcp-1, mip-1, scf, or rantes receptor; or a tnf-α, il6, egf, il1-alpha, il1-beta, g-csf, mcp-1, mip-1, scf, or rantes peptide or fragment thereof.. .
Genesys Research Institute
05/21/15
20150139992
new patent

Baff receptor (bcma), an immunoregulatory agent


A novel receptor in the tnf family is provided: baff-r. Chimeric molecules and antibodies to baff-r and methods of use thereof are also provided..
Biogen Idec Ma Inc.
05/21/15
20150139984
new patent

Active protease-resistant antibody fc mutants


The present invention relates to modified fc-containing molecules including modified antibodies characterized by increased resistance to host and pathogen-derived proteases, ability to interact with fcγr receptors except with fcγri, and lack of induction of il-10 secretion by macrophages, and methods of using and making them.. .
Janssen Biotech, Inc.
05/21/15
20150139945
new patent

Compositions and methods for immunomodulation in an organism


The present invention relates to a therapeutic polypeptide and methods for its creation and use for modulating an immune response in a host organism in need thereof. In particular, the invention relates to the administration to an organism in need thereof, of an effective amount of a pre-coupled polypeptide complex comprising a lymphokine polypeptide portion, for example il-15 (seq id no: 5, 6), il-2 (seq id no: 10, 12) or combinations of both, and an interleukin receptor polypeptide portion, for example il-15ra (seq id no: 7, 8), il-2ra (seq id no: 9, 11) or combinations of both, for augmenting the immune system in, for example, cancer, scid, aids, or vaccination; or inhibiting the immune system in, for example, rheumatoid arthritis, or lupus.
University Of Connecticut
05/21/15
20150139943
new patent

Chimeric receptors and uses thereof in immune therapy


Disclosed herein are chimeric receptors comprising an extracellular domain with affinity and specific for the fc portion of an immunoglobulin molecule (ig) (e.g., an extracellular ligand-binding domain of f158 fcgr3a or v158 fcgr3a variant); a transmembrane domain (e.g., a transmembrane domain of cd8α); at least one co-stimulatory signaling domain (e.g., a co-stimulatory signaling domain of 4-1bb); and a cytoplasmic signaling domain comprising an immunoreceptor tyrosine-based activation motif (itam) (e.g., a cytoplasmic signaling domain of cd3ζ). Also provided herein are nucleic acids encoding such chimeric receptors and immune cells expressing the chimeric receptors.
St. Jude Children's Research Hospital
05/21/15
20150139916
new patent

Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity


Compounds of formula (i) defined herein act both as muscarinic receptor antagonists and beta2 adrenergic receptor agonists and are useful for the prevention and/or treatment of broncho-obstructive or inflammatory diseases.. .
Chiesi Farmaceutici S.p.a.
05/21/15
20150139908
new patent

Labeling composition for intraocular tissue, labeling intraocular tissue, and screening method


The invention provides a labeling composition for an intraocular tissue of a living individual, which specifically labels the intraocular tissue without need of an invasive operation such as exposure of an ocular tissue or injection of a staining agent into the ocular tissue or a nerve tissue linking to the ocular tissue, a method of noninvasively labeling an intraocular tissue of a living individual, and a screening method using the labeling composition for the intraocular tissues. The composition contains a compound capable of labeling at least a photoreceptor cell layer of a retina, wherein the compound is a staining compound having a particular structure as a partial structure thereof..
Canon Kabushiki Kaisha
05/21/15
20150139670
new patent

Method for operating an imaging device with a failed media bin level sensor


A method of operating an imaging device having a failed or failing media-full sensor determines whether or not a controller can trust the output signal received from the media-full sensor. A reduced power or intensity level is used to test the media-full sensor and, in particular, the light source to counter the dimming of the light source that occurs due to aging and electrical noise in the system.
Lexmark International, Inc.
05/21/15
20150138632
new patent

Slide tray and receptor for microscopic slides and operation


A receptor is mounted on a movable stage of a microscope slide scanner, the receptor being sized and shaped to receive a slide tray having one or more microscope slides thereon. A docking station automatically locks the receptor relative to the docking station whenever a tray is inserted or removed from the receptor without transmitting force to the movable stage..
Huron Technologies International Inc.
05/21/15
20150138296
new patent

Dynamic adjustable focus for led writing bars using piezoelectric stacks


According to aspects of the embodiments, there is provided methods of dynamically focusing an led print bar or printhead using piezoelectric stacks. The stack is mounted on either end of the led bar to adjust the focus of the bar against the photoreceptor surface.
Xerox Corporation
05/14/15
20150133663

Novel synthesis method


The present invention relates to a method of making compounds having affinity for the 1 a subtype of the serotonin receptor, i.e. 5ht1a.
05/14/15
20150133637

P2x7 receptor antagonists and agonists


The present invention relates to biological materials against p2x7 and more in particular to polypeptides, nucleic acids encoding such polypeptides; to methods for preparing such polypeptides; to host cells expressing or capable of expressing such polypeptides; to compositions and in particular to pharmaceutical compositions that comprise such polypeptides, for prophylactic, therapeutic or diagnostic purposes. In particular, the biological materials of the present invention inhibit the biological activity of the p2x7 receptor, such as activation by atp..
05/14/15
20150133516

Methods and compositions for treating adhd


The present invention provides compositions and methods of using α2 adrenergic receptor agonists as treatments for adhd. The α2 adrenergic receptor agonist for use with these methods is a benzimidazole derivative, and may be specifically n-(4,5-dihydro-1h-imidazol-2-yl)-7-cyano-4-methyl-1h-benzimidazol-5-amine acetate.
05/14/15
20150133505

Arylethynyl derivatives


It has been found that the compounds of general formula i are allosteric modulators of the metabotropic glutamate receptor subtype 5 (mglur5).. .
05/14/15
20150133498

Benzofuran compounds, compositions, kits and/or methods thereof


Benzofuran compound, composition thereof, kit thereof, and/or method thereof. A benzofuran-2-carboxamide moiety may be n-arylated and/or n-alkylated, and the resulting benzofuran compound may be a sigma receptor ligand that binds to, e.g., a σ1 receptor and/or a σ2 receptor with relatively high affinity and/or selectivity.
05/14/15
20150133491

Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity


Compounds of formula (i) described herein act both as muscarinic receptor antagonists and beta2 adrenergic receptor agonists and are useful for the prevention and/or treatment of broncho-obstructive or inflammatory diseases.. .
05/14/15
20150133481

Crystalline forms of an androgen receptor modulator


Described herein are amorphous and crystalline forms of the androgen receptor modulator 4-[7-(6-cyano-5-trifluoromethylpyridin-3-yl)-8-oxo-6-thioxo-5,7-diazaspiro[3.4]oct-5-yl]-2-fluoro-n-methylbenzamide. Also described are pharmaceutical compositions suitable for administration to a mammal that include the androgen receptor modulator, and methods of using the androgen receptor modulator, alone and in combination with other compounds, for treating diseases or conditions that are associated with androgen receptor activity..
05/14/15
20150133479

Pyrimidinylpiperidinyloxypyridone analogues as gpr119 modulators


Novel compounds of structure formula i: (i) or an enantiomer, a diastereomer, or a pharmaceutically acceptable salt thereof, wherein r1, r2 and r3 are defined herein, are provided which are gpr119 g protein-coupled receptor modulators. Gpr119 g protein-coupled receptor modulators are useful in treating, preventing, or slowing the progression of diseases requiring gpr119 g protein-coupled receptor modulator therapy.
05/14/15
20150133456

Fluoroergoline derivatives and uses thereof


Provided herein are novel fluoroergoline derivatives and compositions thereof. In other embodiments, provided herein are methods of treatment, prevention, or amelioration of a variety of medical disorders such as, for example, migraine using the compounds and compositions disclosed herein.
05/14/15
20150133446

Imidazothiadiazole derivatives as protease activated receptor 4 (par4) inhibitors for treating platelet aggregation


The present invention provides imidazothiadiazole compounds of formula (i) wherein a, b, d, rx, r1, r2, r3, x1, x2 and s are as defined herein, or a stereoisomer, tautomer, pharmaceutically acceptable salt or solvate form thereof, wherein all of the variables are as defined herein. These compounds are inhibitors of platelet aggregation and thus can be used as medicaments..
05/14/15
20150133439

Quinazoline derivatives as kinase inhibitors


The present invention relates to nitrogen-containing heterocyclic compounds and pharmaceutically acceptable salts thereof which have inhibitory activity on the phosphorylation of kinases, which inhibits the activity of such kinases. The invention is also related to a method of inhibiting kinases and treating disease states in a mammal by inhibiting the phosphorylation of kinases.
05/14/15
20150133389

Na+/k+-atpase-specific peptide inhibitors/activators of src and src family kinases


A method for regulating src and its downstream signaling pathway which includes binding between src and na+/k+-atpase is disclosed. The na+/k+-atpase/src complex is a functional receptor for cardiotonic steroids such as ouabain.
05/14/15
20150133383

Method for diagnosis and treatment of prolactin associated disorders


The present invention concerns methods and tools for determining a specific treatment of a prolactin associated disorder. The treatment is selected based on the expression pattern of growth hormonereceptor (ghr), prolactin receptor (prlr) and the suppressors socs2 and tcs2..
05/14/15
20150133376

Evaluation of cancer diagnosis following cancer radiotherapy and potentiation of cancer radiotherapy


A method for evaluation of cancer diagnosis following cancer radiotherapy, comprising: providing a serum sample of a cancer patient prior to the cancer radiotherapy; and measuring a leukemia inhibitory factor concentration in the serum sample. Also provided is a method for potentiation of cancer radiotherapy, comprising: administrating a leukemia inhibitory factor inhibitor or a leukemia inhibitory factor receptor inhibitor to a subject in need of the cancer radiotherapy..
05/14/15
20150133372

Methods and compositions for the induction of hypothermia


Provided herein are methods for the induction of hypothermia and the treatment of clinical insults in a subject through the administration of a regulated hypothermic multidrug combination. The compositions or multidrug combinations of the invention comprise a regulated hypothermic compound or a dopamine receptor agonist; a vasoactive compound; and an antiarrhythmic compound or a serotonin 5-ht3 receptor antagonist.
05/14/15
20150133363

Glut-1 as a receptor for htlv envelopes and its uses


The present application relates to polypeptides derived from the soluble part of the glycoprotein of the enveloped virus of primate t-cell leukemia virus (ptlv), or fragments or variants thereof named receptor binding domain ligands (rbd) selected for their ability to bind specifically to the nutrient transporter glut1.. .


Popular terms: [SEARCH]



Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Receptor for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Receptor with additional patents listed. Browse our RSS directory or Search for other possible listings.
     SHARE
  
         















0.3546

3318

2 - 1 - 72